Resources
Practical guidance for biotech startups navigating NIH SBIR/STTR strategy, summary statements and resubmission, reviewer expectations, and the broader non-dilutive funding landscape.
Checked November 14, 2026
NCI’s November 17 webinar for biotech innovators will cover changes following the 2026 reauthorization, the NCI funding path from early concept through commercialization, and mechanisms including Fast Track, Direct-to-Phase II, Phase IIB and the new Strategic Breakthrough Awards.
NCI SBIR · webinar and registration ↗USDA NIFA’s FY2026 Phase II SBIR/STTR opportunity lists a November 17, 2026 closing date and an amended notice posted October 21. Companies developing agricultural or food-related technologies should review the full notice for prior-award eligibility, topic fit, and submission requirements.
USDA NIFA · opportunity and amended notice ↗NIH’s continuing resolution maintains operations at FY2026 funding levels through December 11, 2026. Institutes and centers may issue non-competing awards below previously indicated levels; recipients should monitor spending and discuss award-specific adjustments with their grants management specialist.
NIH · NOT-OD-26-131 ↗NIH will continue modified review practices for the January 2027 Advisory Council. Applications designated competitive but not discussed remain under funding consideration. Summary statements retain assigned-reviewer critiques; discussion summaries use a consensus statement and score-driving bullet points.
NIH · NOT-OD-26-114 ↗NIH’s guidance explains how to assess ownership, key personnel, consultants, and research partners before applying, and what disclosures follow during Just-in-Time review.
NIH guidance ↗The revised policy caps covered submissions at nine per small business per fiscal year: new and resubmission Phase I, Fast-Track, and Direct to Phase II applications and contract proposals. This notice replaces the April guidance.
NIH · NOT-OD-26-090 ↗The next standard receipt date for the parent SBIR (PA-27-100) and STTR (PA-27-102) opportunities is January 5, 2027. Check the current announcement, participating institutes, eligibility, and required registrations before committing to an application.
NCI · parent SBIR/STTR announcements ↗Award size, competition, preparation costs, and timing: assessing whether an NIH SBIR/STTR application is worth pursuing.
Read insight →Federal agency budgets, NIH award mechanisms and success rates, and related non-dilutive funding pathways.
Read insight →Evidence for follow-on investment, technical feedback, and planning benefits beyond the award.
Read insight →Research plans, registration dependencies, university coordination, and NIH submission requirements.
Read insight →How to interpret reviewer concerns and decide whether another application is justified.
Read insight →HHS foreign-risk criteria, pre-award screening, and continuing disclosure obligations.
Read insight →Your next funding decision
Tell me what your company is pursuing, where you are in the process, and what decision or review you need help with.
Discuss your funding strategy